IR@PKUHSC  > 北京大学基础医学院  > 免疫学系
学科主题基础医学
The specific immune response to tumor antigen CP1 and its correlation with improved survival in colon cancer patients
Liu, Fang-Fang1,2,3; Dong, Xue-Yuan1; Pang, Xue-Wen1; Xing, Qiao1; Wang, Hong-Cheng1; Zhang, Hua-Gang1; Li, Yan1; Yin, Yan-Hui1; Fant, Michael4; Ye, Ying-Jiang2; Shen, Dan-Hua3; Zhang, Yu1; Wang, Shan2; Chen, Wei-Feng1
刊名GASTROENTEROLOGY
2008-04-01
DOI10.1053/j.gastro.2008.01.029
134期:4页:998-1006
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Gastroenterology & Hepatology
研究领域[WOS]Gastroenterology & Hepatology
关键词[WOS]CD8(+) T-CELL ; HUMAN COLORECTAL-CANCER ; CARCINOEMBRYONIC ANTIGEN ; PROTEASOMAL CLEAVAGE ; CARCINOMA PATIENTS ; PLUS IRINOTECAN ; DENDRITIC CELLS ; VACCINATION ; PLACENTA ; PLAC1
英文摘要

Background & Aims: The present study was undertaken to determine the expression of a newly identified tumor antigen cancer-placenta I (CP1) in colorectal carcinoma (CRC) and explore the CP1-specific immune response in CRC patients and its correlation with patient survival. Methods: CP1 expression was determined by reverse-transcription polymerase chain reaction, immunohistochemistry, and Western blot analysis. Serum antibodies against CP1 were detected by enzyme-linked immunosorbent assay, and T-cell response was measured by interferon-gamma/granzyme-B release enzyme-linked immunospot assays. The HLA-A2-restricted epitopes in CP1 were predicted by bioinformatics and then experimentally validated by enzyme-linked immunospot assay. Results: CP1 expression was detected in a significant number of CRC tissues, reaching 47.6% at the messenger RNA (mRNA) level and 28.6% at the protein level. Of patients with CP1 mRNA(+) tumors, more than 50% had CP1-responsive CD4(+) and CD8(+) T cells and 30% spontaneous-occurring antibodies against CP1. Further studies revealed 2 dominant HLA-A2-restricted epitopes in the CP1 antigen: p31-39 and p58-66. In a follow-up study up to 33 months after surgery, 9 of the 10 patients with CP1-specific CD8 T-cell response survived, whereas 6 of the 8 nonresponders died. Kaplan-Meier analysis indicated a significant correlation between T-cell response and patient survival. Conclusions: CP1 represents a new class of tumor-specific shared antigen. Its high expression in CRC tissues, prevalence of CP1-specific immune responses in CP1 mRNA+ CRC patients, and positive correlation with survival suggest that the antigen may be a useful target for cancer immunotherapy.

语种英语
WOS记录号WOS:000254853800020
引用统计
被引频次:23[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
版本出版稿
条目标识符http://ir.bjmu.edu.cn/handle/400002259/60914
专题北京大学基础医学院_免疫学系
北京大学基础医学院
北京大学第二临床医学院_病理科
作者单位1.Peking Univ, Hlth Sci Ctr, Dept Immunol, Beijing 100083, Peoples R China
2.Peking Univ, Peoples Hosp, Dept Surg Gastroenterol, Surg Oncol Lab, Beijing 100044, Peoples R China
3.Peking Univ, Peoples Hosp, Dept Pathol, Beijing 100871, Peoples R China
4.Univ Texas Houston, Hlth Sci Ctr, Dept Pediat, Houston, TX 77225 USA
推荐引用方式
GB/T 7714
Liu, Fang-Fang,Dong, Xue-Yuan,Pang, Xue-Wen,et al. The specific immune response to tumor antigen CP1 and its correlation with improved survival in colon cancer patients[J]. GASTROENTEROLOGY,2008,134(4):998-1006.
APA Liu, Fang-Fang.,Dong, Xue-Yuan.,Pang, Xue-Wen.,Xing, Qiao.,Wang, Hong-Cheng.,...&Chen, Wei-Feng.(2008).The specific immune response to tumor antigen CP1 and its correlation with improved survival in colon cancer patients.GASTROENTEROLOGY,134(4),998-1006.
MLA Liu, Fang-Fang,et al."The specific immune response to tumor antigen CP1 and its correlation with improved survival in colon cancer patients".GASTROENTEROLOGY 134.4(2008):998-1006.
条目包含的文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
1-s2.0-S001650850800(1111KB)期刊论文出版稿开放获取CC BY-NC-SA浏览 请求全文
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Liu, Fang-Fang]的文章
[Dong, Xue-Yuan]的文章
[Pang, Xue-Wen]的文章
百度学术
百度学术中相似的文章
[Liu, Fang-Fang]的文章
[Dong, Xue-Yuan]的文章
[Pang, Xue-Wen]的文章
必应学术
必应学术中相似的文章
[Liu, Fang-Fang]的文章
[Dong, Xue-Yuan]的文章
[Pang, Xue-Wen]的文章
相关权益政策
暂无数据
收藏/分享
文件名: 1-s2.0-S0016508508001030-main.pdf
格式: Adobe PDF
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。